What is Beacon Biosignals?
Founded in 2019 and based in Boston, Massachusetts, Beacon Biosignals is at the forefront of neurotechnology. The company applies artificial intelligence to electroencephalography (EEG) data to unlock precision medicine for a wide spectrum of brain-affecting conditions. This innovative approach aims to provide more accurate diagnostics and personalized treatment strategies, positioning Beacon Biosignals as a key player in the rapidly evolving field of brain-computer interfaces and neurological disorder management.
How much funding has Beacon Biosignals raised?
Beacon Biosignals has raised a total of $210M across 3 funding rounds:
Series A
$27M
Series B
$86M
Series B
$97M
Series A (2021): $27M with participation from Casdin Capital and General Catalyst
Series B (2025): $86M led by S32, Indicator Ventures Select I, Catalio Capital Management, Innoviva, Casdin Capital, Takeda Pharmaceutical Company, GV, Nexus NeuroTech Ventures, Logos Capital, and General Catalyst
Series B (2026): $97M supported by Palo Santo, Kicker Ventures, Nexus NeuroTech Ventures, Samsung NEXT, Innoviva, and jslhealth.com
Key Investors in Beacon Biosignals
Palo Santo
Palo Santo is a U.S.-based psychedelic healthcare investment fund focused on increasing the supply of clinically effective and accessible mental health and addiction treatment solutions. The firm targets a diverse range of companies offering innovative solutions across biopharma, drug development, digital therapeutics, healthcare services, and tech-enabled solutions.
Nexus NeuroTech Ventures
Nexus NeuroTech Ventures is dedicated to advancing breakthrough technologies aimed at addressing neurological and psychiatric disorders. Founded in 2023, the company focuses on investing in a diverse range of medical technologies, from diagnostic tools to treatment interventions.
Innoviva
Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. It partners with companies that advance innovative therapies for improving patient care and building long-lasting value.
What's next for Beacon Biosignals?
The substantial capital infusion, particularly the recent major strategic investment, signals Beacon Biosignals' transition into a scaling phase. This financing is expected to accelerate product development, expand clinical trials, and enhance market penetration. The company's focus on AI-driven EEG analysis for precision brain medicine positions it for significant growth and impact in addressing unmet needs across various neurological and psychiatric disorders.
See full Beacon Biosignals company page
